Sorafenib-induced pancreatitis

Ayyildiz, Talat; Aydin, Taner; Eminler, Ahmet; Yildirim, Cinar; Irak, Kader; KIYICI, MURAT; GÜREL, SELİM; NAK, SELİM; GÜLTEN, MACİT; Dolar, MAHMUT

doi:10.5835/jecm.omu.32.03.008

Sorafenib-induced pancreatitis

Atıf İçin Kopyala

Ayyildiz T., Aydin T., Eminler A. T., Yildirim C., Irak K., KIYICI M., ...Daha Fazla

Journal of Experimental and Clinical Medicine (Turkey), cilt.32, sa.3, ss.133-135, 2015 (Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 32 Sayı: 3
Basım Tarihi: 2015
Doi Numarası: 10.5835/jecm.omu.32.03.008
Dergi Adı: Journal of Experimental and Clinical Medicine (Turkey)
Derginin Tarandığı İndeksler: Scopus, TR DİZİN (ULAKBİM)
Sayfa Sayıları: ss.133-135
Bursa Uludağ Üniversitesi Adresli: Evet

Özet

© 2015 OMU.Sorafenib is an inhibitor of multikinase proteins which is used for metastatic renal cell carcinoma and advanced stage hepatocellular carcinoma. Its side effects include serum amylase and lipase elevations anticipated to occur within first weeks of treatment but clinically and radiologically evident acute pancreatitis develops rarely. Five cases of acute pancreatitis have been reported in literature until date. The case we described here is the sixth case of clinically diagnosed acute pancreatitis.